Remission · Participants with Crohn's disease in remission
Budesonide 6 mg showed no clear difference in continued remission at 3 months compared with budesonide 3 mg (moderate certainty).
3 findings from 1 review
RR 1.07 [0.85, 1.34]
3 studies · 180 participants
Moderate
RR 1.12 [0.85, 1.47]
3 studies · 180 participants
Moderate
RR 1.18 [0.85, 1.65]
3 studies · 180 participants
Moderate
Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease
Methotrexate showed no clear difference in failure to enter remission or possible remission at 16 weeks (Arora… compared with placebo (low certainty).
3 findings from 1 review
RR 3 [0.68, 13.31]
1 study · 33 participants
Low
RR 1.05 [0.79, 1.39]
1 study · 52 participants
Low
RR 0.75 [0.61, 0.93]
1 study · 141 participants
Moderate
Adverse events (Ardizzone 2003) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes adverse events (Ardizzone 2003) compared with 6‐MP or azathioprine (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes withdrawal due to adverse event (Oren 1997) compared with 6‐MP or azathioprine (very low certainty).
3 findings from 1 review
RR 1.23 [0.08, 18.74]
1 study · 58 participants
Very low
RR 2.13 [0.22, 21.17]
1 study · 31 participants
Very low
RR 1 [0.22, 4.52]
1 study · 54 participants
Very low
Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes failure to enter remission or possible remission at 30 weeks… compared with 5‐ASA (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes withdrawal due to adverse event (Maté‐Jiménez 2000) compared with 5‐ASA (very low certainty).
1 finding from 1 review
Failure to enter remission at 14 weeks or 24 weeks (Feagan 2014) · adult patients with refractory Crohn's disease
Methotrexate + infliximab showed no clear difference in failure to enter remission at 14 weeks or 24 weeks (Feagan 2014) compared with infliximab alone (low certainty).
2 findings from 1 review
Adverse events (Schröder 2006) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate + infliximab changes adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
1 finding from 1 review
Serious adverse events (Schröder 2006) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adult patients with refractory Crohn's disease
Methotrexate + infliximab showed no clear difference in withdrawals due to adverse event (Feagan 2014) compared with infliximab alone (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adult patients with refractory Crohn's disease
Methotrexate may leads to higher withdrawal due to adverse event (Feagan 1995) compared with placebo (low certainty).
3 findings from 1 review
RR 8 [1.09, 58.51]
1 study · 141 participants
Low
RR 3 [0.13, 70.42]
1 study · 52 participants
Low
RR 8.31 [0.46, 149.21]
1 study · 33 participants
Low
Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease
Methotrexate showed no clear difference in failure to enter remission or possible remission at 24‐36 weeks… compared with 6‐MP or azathioprine (low certainty).
3 findings from 1 review
RR 1.36 [0.97, 1.92]
1 study · 58 participants
Low
RR 3.2 [0.37, 27.49]
1 study · 31 participants
Very low
RR 1.2 [0.63, 2.29]
1 study · 54 participants
Very low
Intervention not reported
Relapse rate at one year (all studies) · Crohn's disease patients in remission
It is very uncertain whether the intervention changes relapse rate at one year (all studies) (very low certainty).
1 finding from 1 review
Intervention not reported
Relapse rate at one year (sensitivity analysis of Belluzi 1996) · Crohn's disease patients in remission
It is very uncertain whether the intervention changes relapse rate at one year (sensitivity analysis of Belluzi 1996) (very low certainty).
1 finding from 1 review
Intervention not reported
Relapse rate at one year (only EPIC studies) · Crohn's disease patients in remission
The intervention showed no clear difference in relapse rate at one year (only EPIC studies) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events rate‐Diarrhea · Crohn's disease patients in remission
The intervention probably leads to higher adverse events rate‐Diarrhea (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events rate‐ Upper GI (nausea, vomiting, halitosis, heartburn, dyspepsia, dysgeusia and bloating) · Crohn's disease patients in remission
The intervention probably leads to higher adverse events rate‐ Upper GI (nausea, vomiting, halitosis,… (moderate certainty).
1 finding from 1 review
Maintenance of clinical remission · Participants with Crohn's disease in remission
Methotrexate probably leads to higher proportion of patients maintaining clinical remission compared with placebo (moderate certainty).
3 findings from 1 review
RR 1.57 [1.1, 2.23]
2 studies · 98 participants
Moderate
RR 1.67 [1.05, 2.67]
1 study · 76 participants
Moderate
RR 1.35 [0.86, 2.12]
1 study · 22 participants
Low
Maintenance of clinical remission · Participants with Crohn's disease in remission
It is very uncertain whether methotrexate changes proportion of patients maintaining clinical remission compared with 6‐mercaptopurine (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · maintenance of remission in Crohn's disease
Methotrexate + infliximab showed no clear difference in proportion of patients maintaining remission compared with infliximab +/‐ placebo (low certainty).
1 finding from 1 review